Flavopiridol, a cyclin-dependent kinase inhibitor;Le flavopiridol, une proteine kinase dependante des cyclines

Bulletin du Cancer

Volumn 87, Issue 10, 2000, Pages 697-701

  Lansiaux, A ^a   Bailey, C ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLAVOPIRIDOL; PACLITAXEL; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; FLAVONOID; PIPERIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG UTILIZATION; ENZYME INHIBITION; HUMAN; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STRUCTURE ANALYSIS; TUMOR REGRESSION; APOPTOSIS; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; MULTIDRUG RESISTANCE; NEOPLASM; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; HUMANS; NEOPLASMS; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033724646     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Cyclin-dependent kinases: Engines, clocks, and microprocessors
2. The role of RB in cell cycle control
3. Cancer cell cycles
4. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
5. Cydin-dependent kinases: Initial approaches to exploit a novel therapeutic target
6. Structure-activity relationship studies of flavopiridol analogues
7. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
8. An anti-inflammatory immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: Isolation, structure and total synthesis
9. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy
10. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
11. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CKD4 in human breast carcinoma cells
12. Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase
13. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
14. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis
15. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers
16. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activity
17. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
18. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
19. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
20. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
21. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
22. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
23. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
24. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
25. Cell cycleindependent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
26. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
27. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
28. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol
29. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities
30. Potent interaction of flavopiridol with MRP1
31. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
32. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence administration
33. Potentiation of apoptosis by flavopiridol in mitomycin C-treated gastric and breast cancer cells
34. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel treated human gastric and breast cancer cells
35. Phase I trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol
36. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells
37. Flavopiridol binds to duplex DNA
38. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells
39. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
40. Phase I clinical and pharmacokinetic trial of flavopiridol
41. Preclinical and clinical development of cyclin-dependent kinase modulators
42. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II Consortium study
43. The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
44. A phase II trial of flavopiridol in patients with stage IV non-small cell lung
45. Phase II of flavopiridol in metastatic colorectal cancer: Preliminary results
46. Flavopiridol enhances the biological effects of paclitaxel: A phase I trial in patients with advanced solid tumors
47. Phase I trial of sequential paclitaxel and cisplatin in combination with cyclin dependent kinase flavopiridol in patients with advanced solid tumors